Clinical Trials Directory

Trials / Completed

CompletedNCT01001091

AL-38583 Ophthalmic Solution for Allergic Conjunctivitis Associated Inflammation

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
312 (actual)
Sponsor
Alcon Research · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to assess the safety and efficacy of AL-38583 in the treatment of the signs of inflammation associated with allergic conjunctivitis.

Conditions

Interventions

TypeNameDescription
DRUGAL-38583 ophthalmic solution
DRUGAL-38583 ophthalmic solution vehicleInactive ingredients used as a placebo comparator
DRUGDexamethasone ophthalmic suspension, 0.1%

Timeline

Start date
2009-12-01
Primary completion
2010-04-01
Completion
2010-04-01
First posted
2009-10-23
Last updated
2014-07-17

Source: ClinicalTrials.gov record NCT01001091. Inclusion in this directory is not an endorsement.

AL-38583 Ophthalmic Solution for Allergic Conjunctivitis Associated Inflammation (NCT01001091) · Clinical Trials Directory